Lonnie Moulder, Zenas BioPharma CEO
August 22, 2024 03:27 PM EDTUpdated August 23, 08:12 AM
Financing
Startups

Au­toim­mune biotech Zenas files for IPO amid sum­mer lull for pub­lic de­buts

Kyle LaHucik

Senior Reporter

Zenas Bio­Phar­ma filed for an ini­tial pub­lic of­fer­ing on Thurs­day, mark­ing a rare move for biotech star­tups this sum­mer.

The late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times